Abstract
OBJECTIVE: Cushing’s disease during pregnancy is associated with an increased risk for maternal and fetal complications. In recurrent Cushing’s disease following transsphenoidal surgery, and when re-operation is not feasible, medical treatment is usually considered. Cabergoline was found to be effective in reducing hypercortisolism in Cushing’s disease. Evolving data concerning the safety of cabergoline use during pregnancy show no significant increase in the rate of complications during pregnancy or the postnatal period. METHODS: We report a 29-year-old woman, gravida 0, para 0, with recurrent Cushing’s disease, three years after transsphenoidal resection of pituitary ACTH-secreting macroadenoma. Repeated MRI revealed an empty sella with a small gadolinium-enhancing lesion, suspected to be an adenoma remnant on the medial wall of the right cavernous sinus. As the patient was not willing to undergo repeat surgical intervention, treatment with cabergoline was initiated, with a gradual dose titration up to 3.5 mg/week. Clinical improvement ensued, and 4 months later, she conceived spontaneously. After discussing treatment options with the patient, cabergoline treatment at a dose of 2 mg/week was continued throughout pregnancy. RESULTS: The patient showed complete clinical remission during pregnancy. Consecutive tests of 24-h urinary free Cortisol concentration were not found to be elevated. Pregnancy and delivery were uneventful except for mild hypothyroidism observed during the second trimester. At full term the patient delivered a healthy female infant, by an elective cesarean section. CONCLUSION: This case report demonstrates that cabergoline may be an effective and safe therapeutic option for the treatment of Cushing’s disease during pregnancy.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Lado-Abeal J, Rodriguez-Arnao J, Newell-Price JD, et al, 1998 Menstrual abnormalities in women with Cushing’s disease are correlated with hypercortisolemia rather than raised circulating androgen levels. J Clin Endocrinol Metab 83: 3083.
Lindsay JR, Jonklaas J, Oldfield EH, Nieman LK, 2005 Cushing’s syndrome during pregnancy: personal experience and review of the literature. J Clin Endocrinol Metab 90: 3077–3083.
Nieman LK, Biller BM, Findling JW, et al, 2008 The diagnosis of Cushing’s syndrome: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 93: 1526–1540.
Lindsay JR, Jonklaas J, Oldfield EH, Nieman LK, 2005 Cushing’s syndrome during pregnancy: personal experience and review of the literature. J Clin Endocrinol Metab 90: 3077–3083.
Biller BM, Grossman AB, Stewart PM, et al, 2008 Treatment of adrenocorticotropindependent Cushing’s syndrome: a consensus statement. J Clin Endocrinol Metab 93: 2454–2462.
Lim WH, Torpy DJ, Jeffries WS, 2013 The medical management of Cushing’s syndrome during pregnancy. Eur J Obstet Gynecol Reprod Biol 168: 1–6.
Prebtani AP, Donat D, Ezzat S, 2000 Worrisome striae in pregnancy. Lancet 355: 1692.
Amado JA, Pesquera C, Gonzalez EM, Otero M, Freijanes J, Alvarez A, 1990 Successful treatment with ketoconazole of Cushing’s syndrome in pregnancy. Postgrad Med J 66: 221–223.
Berwaerts J, Verhelst J, Mahler C, Abs R, 1999 Cushing’s syndrome in pregnancy treated by ketoconazole: case report and review of the literature. Gynecol Endocrinol 13: 175–182.
Boronat M, Marrero D, López-Plasencia Y, Barber M, Schamann Y, Nóvoa FJ, 2011 Successful outcome of pregnancy in a patient with Cushing’s disease under treatment with ketoconazole during the first trimester of gestation. Gynecol Endocrinol 27: 675–677.
Kazy Z, Puho’ E, Czeizel AE, 2005 Population-based case-control study of oral ketoconazole treatment for birth outcomes. Congenit Anom (Kyoto) 45: 5–8.
Leiba S, Weinstein R, Shindel B, et al, 1989 The protracted effect of o,p’-DDD in Cushing’s disease and its impact on adrenal morphogenesis of young human embryo. Ann Endocrinol (Paris) 50: 49–53.
Tripto-Shkolnik L, Blumenfeld Z, Bronshtein M, Salmon A, Jaffe A, 2013 Pregnancy in a patient with adrenal carcinoma treated with mitotane: A case report and review of literature. J Clin Endocrinol Metab 98: 443–447.
Pivonello R, Ferone D, de Herder WW, et al, 2004 Dopamine receptor expression and function in corticotroph pituitary tumors. J Clin Endocrinol Metab 89: 2452–2462.
Pivonello R, De Martino MC, Cappabianca P, et al, 2009 The medical treatment of Cushing’s disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery. J Clin Endocrinol Metab 94: 223–230.
Godbout A, Manavela M, Danilowicz K, Beauregard H, Bruno OD, Lacroix A, 2010 Cabergoline monotherapy in the long-term treatment of Cushing’s disease. Eur J Endocrinol 163: 709–716.
Turkalj I, Braun P, Krupp P, 1982 Surveillance of bromocriptine in pregnancy. JAMA 247: 1589–1591.
Krupp P, Monka C, 1987 Bromocriptine in pregnancy: safety aspects. Klin Wochenschr 65: 823–827.
Weil C, 1986 The safety of bromocriptine in hyperprolactinaemic female infertility: a literature review. Current Medical Research and Opinion 10: 172–195.
Colao A, Abs R, Bárcena DG, Chanson P, Paulus W, Kleinberg D, 2008 Pregnancy outcomes following cabergoline treatment: extended results from a 12-year observational study. Clin Endocrinol (Oxf) 68: 66–71.
Lebbe M, Hubinont C, Bernard P, Maiter D, 2010 Outcome of 100 pregnancies initiated under treatment with cabergoline in hyperprolactinaemic women. Clin Endocrinol 73: 236–242.
Stalldecker G, Mallea-Gil MS, Guitelman M, 2010 Effects of cabergoline on pregnancy and embryo-fetal development: Retrospective study on 103 pregnancies and a review of the literature. Pituitary 13: 345–350.
Glezer A, Bronstein MD, 2014 Prolactinomas, cabergoline, and pregnancy. Endocrine 47: 64–69.
Woo I, Ehsanipoor RM, 2013 Cabergoline therapy for cushing disease throughout pregnancy. Obstet Gynecol 122: 485–487.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Nakhleh, A., Saiegh, L., Reut, M. et al. Cabergoline treatment for recurrent Cushing’s disease during pregnancy. Hormones 15, 453–458 (2016). https://doi.org/10.14310/horm.2002.1685
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.14310/horm.2002.1685